Silexion Therapeutics - Warrants(14/08/2029) EBIT

The latest EBIT for SLXNW is $-4.4M as of June 2026. That compares with $-12M in the prior-year period — up 64.0% year over year. That is below the sector sector average of $2.6T. Investors often review this figure alongside Silexion Therapeutics - Warrants(14/08/2029)'s historical trend and sector peers before judging valuation or financial health.

Over the past year, SLXNW's EBIT moved from $-12M to $-4.4M — a 64.0% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Silexion Therapeutics - Warrants(14/08/2029)'s operating scale or balance-sheet position.

Against its sector companies, SLXNW currently prints $-4.4M for EBIT, while the sector average sits near $2.6T. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Silexion Therapeutics - Warrants(14/08/2029)'s growth, margins, and balance sheet.

A EBIT figure of $-4.4M for SLXNW is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $2.6T. Explore the charts below for those layers of context.

After noting SLXNW's EBIT ($-4.4M), review year-over-year change from $-12M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.